APAC Pancreatic Cancer Therapeutics & Diagnostics Market Size
| Study Period | 2019 - 2029 |
| Base Year For Estimation | 2023 |
| Forecast Data Period | 2024 - 2029 |
| Historical Data Period | 2019 - 2022 |
| CAGR | 6.40 % |
Major Players
*Disclaimer: Major Players sorted in no particular order |
Need a report that reflects how COVID-19 has impacted this market and its growth?
APAC Pancreatic Cancer Therapeutics & Diagnostics Market Analysis
The market studied is majorly driven by the factors such as the increasing prevalence of pancreatic cancer, increasing demand for diagnostic tests and treatment of this disease. As a result, many governments and non-profit organizations have taken initiatives to spread awareness regarding pancreatic cancer in the Asia-Pacific region. Moreover, technological advancements have in diagnostics and treatment have led to solutions that more efficient. These are the major factors that have propelled the market growth.
The high cost of treatment and diagnostics and side effects due to therapies is expected to restrain the market growth.
APAC Pancreatic Cancer Therapeutics & Diagnostics Market Trends
This section covers the major market trends shaping the APAC Pancreatic Cancer Therapeutics & Diagnostics Market according to our research experts:
Radiotherapy is Expected to register a High CAGR
Radiation therapy is a cancer treatment that uses high-energy radiation, in the form of waves, such as x-rays, or particles, such as protons, to kill cancer cells or prevent them from growing and dividing. Radiation therapy can prevent pancreatic tumors from growing and sometimes shrinks them. Since radiation therapy is directed to a specific (focused) area, it is considered a local treatment.
The demand for radiation therapy in Asia-pacific is also expected to increase as stated by the 2018 report by Noorazrul Yahya et al., published in the Asia-pacific Journal of Clinical Oncology. According to the estimates of the report, the number of radiotherapy fractions needed in 2025 and 2035 is expected to increase to 11.1 million and 14.1 million, respectively, compared to 7.6 million in 2015 in Southeast Asia.
As the demand for increases, it is expected that its application in pancreatic cancer will also increase. This is expected to help the market growth in the region.
APAC Pancreatic Cancer Therapeutics & Diagnostics Industry Overview
Most of the countries in Asia-pacific are developing countries. These developing economies have an increasing prevalence of panreatic cancer. As a result, these countries are highly lucrative for global players to enter the market. Hence, this region enjoys the presence of themost of the global player in the pancreatic cancer therapeutics and diagnostics market.
APAC Pancreatic Cancer Therapeutics & Diagnostics Market Leaders
-
Bristol-Myers Squibb
-
Novartis AG
-
F. Hoffmann-La Roche AG
-
Pfizer Inc
-
Eli Lilly and Company
*Disclaimer: Major Players sorted in no particular order
APAC Pancreatic Cancer Therapeutics & Diagnostics Market Report - Table of Contents
1. INTRODUCTION
- 1.1 Study Deliverables
- 1.2 Study Assumptions
- 1.3 Scope of the Study
2. RESEARCH METHODOLOGY
3. EXECUTIVE SUMMARY
4. MARKET DYNAMICS
- 4.1 Market Overview
-
4.2 Market Drivers
- 4.2.1 Increasing Incidence and Prevalence of Pancreatic Cancer
- 4.2.2 Rising Awareness and Concern about the Disease
- 4.2.3 Technological Advancements and Innovation of New Products
-
4.3 Market Restraints
- 4.3.1 High Costs Associated with Treatment and Diagnosis
- 4.3.2 Side Effects of Pancreatic Cancer Therapy
-
4.4 Porter's Five Force Analysis
- 4.4.1 Threat of New Entrants
- 4.4.2 Bargaining Power of Buyers/Consumers
- 4.4.3 Bargaining Power of Suppliers
- 4.4.4 Threat of Substitute Products
- 4.4.5 Intensity of Competitive Rivalry
5. MARKET SEGMENTATION
-
5.1 By Type
- 5.1.1 By Treatment
- 5.1.1.1 Surgery
- 5.1.1.2 Chemotherapy
- 5.1.1.3 Radiation Therapy
- 5.1.1.4 Targeted Therapy
- 5.1.2 By Diagnostics
- 5.1.2.1 Imaging
- 5.1.2.2 Biopsy
- 5.1.2.3 Endoscopy
- 5.1.2.4 Other Diagnostic Tests
-
5.2 By Cancer Type
- 5.2.1 Exocrine Cancers
- 5.2.2 Endocrine Cancers
-
5.3 Geography
- 5.3.1 Asia-Pacific
- 5.3.1.1 China
- 5.3.1.2 Japan
- 5.3.1.3 India
- 5.3.1.4 Australia
- 5.3.1.5 South Korea
- 5.3.1.6 Rest of Asia-Pacific
6. COMPETITIVE LANDSCAPE
-
6.1 Company Profiles
- 6.1.1 Bristol-Myers Squibb
- 6.1.2 Canon Medical Systems
- 6.1.3 Eli Lilly and Company
- 6.1.4 F. Hoffmann-La Roche AG
- 6.1.5 GE Healthcare
- 6.1.6 Hitachi Medical
- 6.1.7 Novartis AG
- 6.1.8 Pfizer Inc
- 6.1.9 Philips Healthcare
- 6.1.10 Siemens AG
- *List Not Exhaustive
7. MARKET OPPORTUNITIES AND FUTURE TRENDS
** Subject To AvailablityAPAC Pancreatic Cancer Therapeutics & Diagnostics Industry Segmentation
Pancreatic cancer happens when uncontrolled cell growth begins in a part of the pancreas. Tumors develop, and these interfere with the way the pancreas works. pancreatic cancer therapeutics and diagnostics involve procedures for successful diagnosis and treatment of the pancreatic cancer.
In the report, a detailed analysis of the Asia-pacific pancreatic cancer therapeutics and diagnostics market is provided. The market is evaluated by collating revenues generated across segments, categorized by Cancer Type, Treatment, Diagnostics, and Geography.
| By Type | By Treatment | Surgery |
| Chemotherapy | ||
| Radiation Therapy | ||
| Targeted Therapy | ||
| By Type | By Diagnostics | Imaging |
| Biopsy | ||
| Endoscopy | ||
| Other Diagnostic Tests | ||
| By Cancer Type | Exocrine Cancers | |
| Endocrine Cancers | ||
| Geography | Asia-Pacific | China |
| Japan | ||
| India | ||
| Australia | ||
| South Korea | ||
| Rest of Asia-Pacific |
APAC Pancreatic Cancer Therapeutics & Diagnostics Market Research FAQs
What is the current Asia-Pacific Pancreatic Cancer Therapeutics & Diagnostics Market size?
The Asia-Pacific Pancreatic Cancer Therapeutics & Diagnostics Market is projected to register a CAGR of 6.40% during the forecast period (2024-2029)
Who are the key players in Asia-Pacific Pancreatic Cancer Therapeutics & Diagnostics Market?
Bristol-Myers Squibb, Novartis AG, F. Hoffmann-La Roche AG, Pfizer Inc and Eli Lilly and Company are the major companies operating in the Asia-Pacific Pancreatic Cancer Therapeutics & Diagnostics Market.
What years does this Asia-Pacific Pancreatic Cancer Therapeutics & Diagnostics Market cover?
The report covers the Asia-Pacific Pancreatic Cancer Therapeutics & Diagnostics Market historical market size for years: 2019, 2020, 2021, 2022 and 2023. The report also forecasts the Asia-Pacific Pancreatic Cancer Therapeutics & Diagnostics Market size for years: 2024, 2025, 2026, 2027, 2028 and 2029.
Asia-Pacific Pancreatic Cancer Therapeutics & Diagnostics Industry Report
Statistics for the 2024 Asia-Pacific Pancreatic Cancer Therapeutics & Diagnostics market share, size and revenue growth rate, created by Mordor Intelligence™ Industry Reports. Asia-Pacific Pancreatic Cancer Therapeutics & Diagnostics analysis includes a market forecast outlook to 2029 and historical overview. Get a sample of this industry analysis as a free report PDF download.
